IC
BIO icon

Inscription Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Inscription Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Sell
1,363
-25
-2% -$7.09K 0.04% 457
2026
Q1 		$387K Sell
1,388
-15
-1% -$4.32K 0.04% 424
2025
Q4 		$425K Buy
1,403
+15
+1% +$4.68K 0.04% 405
2025
Q3 		$389K Buy
+1,388
New +$378K 0.04% 414

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Inscription Capital's BIO Position: Q2 2026 in Review

Inscription Capital reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.8% in Q2 2026, selling an estimated $7.09K and leaving 1,363 shares worth $400K. The position accounts for 0.04% of the portfolio, ranked #457.

Inscription Capital first reported a position in BIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $425K in Q4 2025. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Inscription Capital held 1,363 shares of Bio-Rad Laboratories Class A worth $400K as of Q2 2026.
  • Inscription Capital sold 25 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $7.09K.
  • Bio-Rad Laboratories Class A made up 0.04% of Inscription Capital's portfolio in Q2 2026, its #457 holding.
  • Inscription Capital first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 4 quarters since.
  • Inscription Capital's Bio-Rad Laboratories Class A position peaked at $425K in Q4 2025.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.